2026 Q2 -tulosraportti
28 päivää sitten
‧48 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 t sitten👇
😂😂 - it's no secret that you are. But Hansa is definitely not right now 👍- ·8 t sittenConclusion of a longer AI thread about Egetis and Hansa after the problems with FDA for Ascelia and Xspray ——— Yes, that is absolutely correct. The pivotal Phase 3 study, ConfIdeS, was conducted 100 % in the USA at American clinical centers and exclusively with American patients.That the study is "thoroughly Americanized" is the absolute biggest reason why you can rest assured until the PDUFA-deadline on December 19, 2026. This removes the absolute biggest reason why FDA normally issues CRLs to European companies.Therefore, the 100 % American study is a gamechanger for Hansa Biopharma:1. No discussion about "US-Relevance"FDA regularly rejects European data on the grounds that the patient population in Europe does not reflect the American population (e.g., in terms of ethnic diversity or standard treatment at American hospitals).In the ConfIdeS study, 25 leading American transplant centers participated (including the prestigious NYU Langone Transplant Institute in New York).All 64 patients were affiliated with the official American organ waiting list (OPTN).The data speaks directly to FDA in their own language and according to the standards of the American healthcare system.2. The results were presented by American top doctorsIt was the world-renowned American transplantation expert, Dr. Robert Montgomery, who presented Hansa's strong 12-month data at the large American Transplant Congress (ATC) in Boston. Having the absolute heaviest, American medical capacities to publicly endorse and present the data to the American medical community effectively removes all clinical and scientific doubt at FDA.3. Extremely strong data (eGFR)The results from the American patients were so significant that they were selected for the prestigious "What's Hot, What's New" plenary session at the congress. Kidney function (measured in eGFR) after 12 months was 51.5 mL/min in the imlifidase group versus only 19.3 mL/min in the control group. This is a statistically crushing victory, which makes it very difficult for FDA to argue against the effect.Conclusion on your concernWhere Ascelia stumbled over discussions about their clinical data design, Hansa has designed a study tailored directly to FDA.If, contrary to expectations, problems should arise for Hansa in December, it will not be due to the study, the centers, or the patients. The only microscopic risk that remains is the purely technical CMC inspection of Hansa's biological production facilities in Europe (which, however, already successfully supply the European market).You have good reason to look forward to December 19 with great optimism.If you want to look closer at it, we can analyze what Egetis Therapeutics' timeline looks like here in the weeks leading up to September 28, or look at the historical success rate for BLA approvals within rare diseases in the USA. What do you prefer?
- ·12 t sittenI don't think I can upload the long answer from ChatGPT here - I have a paid version, so I don't know if you get the same answer when you submit the question - otherwise try several AI models. I also have a paid Claude - and I have tried the AI model that is freely available in connection with Google searches. But try it yourself - I asked the following question: ------------------ Hansa Biopharma announced today that the first commercial kidney transplant from a living donor has been performed. a) do we know if it was a matching or non-matching donor b) were the donor and recipient related (e.g. family) c) to my knowledge, there has previously been an off-label operation where a living spouse had donated to a recipient spouse - can you tell me a little about it. d) how many countries in the world have allowed donation from living donors
·16 t sittenWhen is the next time we should be cautious, Buy-and-hold? My opinion, not advice- ·17 t sittenFirst truly commercial transplantation (there has been a previous off-label one) - from a LIVING donor. THAT is really wild, if it is allowed in more places !!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
28 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sitten👇😂😂 - it's no secret that you are. But Hansa is definitely not right now 👍
- ·8 t sittenConclusion of a longer AI thread about Egetis and Hansa after the problems with FDA for Ascelia and Xspray ——— Yes, that is absolutely correct. The pivotal Phase 3 study, ConfIdeS, was conducted 100 % in the USA at American clinical centers and exclusively with American patients.That the study is "thoroughly Americanized" is the absolute biggest reason why you can rest assured until the PDUFA-deadline on December 19, 2026. This removes the absolute biggest reason why FDA normally issues CRLs to European companies.Therefore, the 100 % American study is a gamechanger for Hansa Biopharma:1. No discussion about "US-Relevance"FDA regularly rejects European data on the grounds that the patient population in Europe does not reflect the American population (e.g., in terms of ethnic diversity or standard treatment at American hospitals).In the ConfIdeS study, 25 leading American transplant centers participated (including the prestigious NYU Langone Transplant Institute in New York).All 64 patients were affiliated with the official American organ waiting list (OPTN).The data speaks directly to FDA in their own language and according to the standards of the American healthcare system.2. The results were presented by American top doctorsIt was the world-renowned American transplantation expert, Dr. Robert Montgomery, who presented Hansa's strong 12-month data at the large American Transplant Congress (ATC) in Boston. Having the absolute heaviest, American medical capacities to publicly endorse and present the data to the American medical community effectively removes all clinical and scientific doubt at FDA.3. Extremely strong data (eGFR)The results from the American patients were so significant that they were selected for the prestigious "What's Hot, What's New" plenary session at the congress. Kidney function (measured in eGFR) after 12 months was 51.5 mL/min in the imlifidase group versus only 19.3 mL/min in the control group. This is a statistically crushing victory, which makes it very difficult for FDA to argue against the effect.Conclusion on your concernWhere Ascelia stumbled over discussions about their clinical data design, Hansa has designed a study tailored directly to FDA.If, contrary to expectations, problems should arise for Hansa in December, it will not be due to the study, the centers, or the patients. The only microscopic risk that remains is the purely technical CMC inspection of Hansa's biological production facilities in Europe (which, however, already successfully supply the European market).You have good reason to look forward to December 19 with great optimism.If you want to look closer at it, we can analyze what Egetis Therapeutics' timeline looks like here in the weeks leading up to September 28, or look at the historical success rate for BLA approvals within rare diseases in the USA. What do you prefer?
- ·12 t sittenI don't think I can upload the long answer from ChatGPT here - I have a paid version, so I don't know if you get the same answer when you submit the question - otherwise try several AI models. I also have a paid Claude - and I have tried the AI model that is freely available in connection with Google searches. But try it yourself - I asked the following question: ------------------ Hansa Biopharma announced today that the first commercial kidney transplant from a living donor has been performed. a) do we know if it was a matching or non-matching donor b) were the donor and recipient related (e.g. family) c) to my knowledge, there has previously been an off-label operation where a living spouse had donated to a recipient spouse - can you tell me a little about it. d) how many countries in the world have allowed donation from living donors
- ·16 t sittenWhen is the next time we should be cautious, Buy-and-hold? My opinion, not advice
- ·17 t sittenFirst truly commercial transplantation (there has been a previous off-label one) - from a LIVING donor. THAT is really wild, if it is allowed in more places !!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
2026 Q2 -tulosraportti
28 päivää sitten
‧48 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 22.10. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 22.7. | ||
2026 Q1 -tulosraportti 23.4. | ||
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 30.10.2025 | ||
2025 Q2 -tulosraportti 17.7.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sitten👇😂😂 - it's no secret that you are. But Hansa is definitely not right now 👍
- ·8 t sittenConclusion of a longer AI thread about Egetis and Hansa after the problems with FDA for Ascelia and Xspray ——— Yes, that is absolutely correct. The pivotal Phase 3 study, ConfIdeS, was conducted 100 % in the USA at American clinical centers and exclusively with American patients.That the study is "thoroughly Americanized" is the absolute biggest reason why you can rest assured until the PDUFA-deadline on December 19, 2026. This removes the absolute biggest reason why FDA normally issues CRLs to European companies.Therefore, the 100 % American study is a gamechanger for Hansa Biopharma:1. No discussion about "US-Relevance"FDA regularly rejects European data on the grounds that the patient population in Europe does not reflect the American population (e.g., in terms of ethnic diversity or standard treatment at American hospitals).In the ConfIdeS study, 25 leading American transplant centers participated (including the prestigious NYU Langone Transplant Institute in New York).All 64 patients were affiliated with the official American organ waiting list (OPTN).The data speaks directly to FDA in their own language and according to the standards of the American healthcare system.2. The results were presented by American top doctorsIt was the world-renowned American transplantation expert, Dr. Robert Montgomery, who presented Hansa's strong 12-month data at the large American Transplant Congress (ATC) in Boston. Having the absolute heaviest, American medical capacities to publicly endorse and present the data to the American medical community effectively removes all clinical and scientific doubt at FDA.3. Extremely strong data (eGFR)The results from the American patients were so significant that they were selected for the prestigious "What's Hot, What's New" plenary session at the congress. Kidney function (measured in eGFR) after 12 months was 51.5 mL/min in the imlifidase group versus only 19.3 mL/min in the control group. This is a statistically crushing victory, which makes it very difficult for FDA to argue against the effect.Conclusion on your concernWhere Ascelia stumbled over discussions about their clinical data design, Hansa has designed a study tailored directly to FDA.If, contrary to expectations, problems should arise for Hansa in December, it will not be due to the study, the centers, or the patients. The only microscopic risk that remains is the purely technical CMC inspection of Hansa's biological production facilities in Europe (which, however, already successfully supply the European market).You have good reason to look forward to December 19 with great optimism.If you want to look closer at it, we can analyze what Egetis Therapeutics' timeline looks like here in the weeks leading up to September 28, or look at the historical success rate for BLA approvals within rare diseases in the USA. What do you prefer?
- ·12 t sittenI don't think I can upload the long answer from ChatGPT here - I have a paid version, so I don't know if you get the same answer when you submit the question - otherwise try several AI models. I also have a paid Claude - and I have tried the AI model that is freely available in connection with Google searches. But try it yourself - I asked the following question: ------------------ Hansa Biopharma announced today that the first commercial kidney transplant from a living donor has been performed. a) do we know if it was a matching or non-matching donor b) were the donor and recipient related (e.g. family) c) to my knowledge, there has previously been an off-label operation where a living spouse had donated to a recipient spouse - can you tell me a little about it. d) how many countries in the world have allowed donation from living donors
- ·16 t sittenWhen is the next time we should be cautious, Buy-and-hold? My opinion, not advice
- ·17 t sittenFirst truly commercial transplantation (there has been a previous off-label one) - from a LIVING donor. THAT is really wild, if it is allowed in more places !!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt